The Middle East and Africa generic drugs market was valued at USD 35.45 Billion in 2025, driven by increasing healthcare needs and strategic partnerships in the region. The market is expected to grow at a CAGR of 7.42% during the forecast period of 2026-2035, with the values likely to rise from USD 72.52 Billion by 2035.
Base Year
Historical Period
Forecast Period
The rising healthcare needs in Middle Eastern and African countries, due to the growing burden of chronic diseases and population growth are poised to augment the market demand.
One of the major Middle East and Africa generic drugs market trends is the rise in strategic partnerships between local and international pharmaceutical companies. For instance, in September 2023, Cipla Limited signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African over the counter (OTC) and generic medicines pharmaceutical company to gain entry into the South African market and strengthen its OTC drug offerings.
Healthcare policies in the Middle East and North Africa region are increasingly focusing on reducing healthcare expenditure which is shifting the focus on improving the accessibility and uptake of affordable treatment options, thereby elevating the market value.
Compound Annual Growth Rate
7.42%
Value in USD Billion
2026-2035
*this image is indicative*
A generic drug contains the same active ingredients and offers similar clinical benefits as a brand-name medicine. They are generally marketed at lower prices (an estimated 80 to 85% less ) and thus serve as a cost-effective alternative to patent-protected medications. Healthcare policies in the Middle East and North Africa region are increasingly focusing on reducing healthcare expenditure which is shifting the focus on improving the accessibility and uptake of affordable treatment options, such as generic drugs. Further, the rising investment in healthcare infrastructure, such as hospitals and clinics, especially in under-developed areas, is expected to fuel the Middle East and Africa Generic Drugs market in the coming years.
The rising healthcare needs in the Middle Eastern and African countries, due to the growing burden of chronic diseases and population growth, are significantly contributing to the expansion of the global generic drugs market . The International Diabetes Federation states that diabetes prevalence in the region is projected to reach 136 million cases by 2045. Additionally, obesity is a severe problem in the Middle East and Africa, comprising 18 of the top 50 countries with high obesity rates globally. With the growing prevalence of chronic conditions (needing long-term medications), the Middle East and Africa Generic Drugs market demand is expected to witness a surge in the forecast period.
One of the major market trends is the rise in strategic partnerships between local and international pharmaceutical companies. For instance, in September 2023 , Cipla Limited, an Indian multinational pharmaceutical company signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African-based pharmaceutical company specializing in over the counter (OTC) and generic medicines, at a deal worth USD 48.6 million . The acquisition was intended to enter the South African market and strengthen its OTC drug offerings. Such collaborations also allow the regional players to utilize advanced technology and expertise, which helps them to improve the manufacturing efficiency and quality of generic drugs. Thus, the increasing merger and acquisition activities are anticipated to boost the market share.
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Area
Market Breakup by Route of Administration
Market Breakup by Distribution Channels
Market Breakup by Region
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 35.45 Billion in 2025 driven by increasing healthcare needs and strategic partnerships in the region.
The market is anticipated to grow at a CAGR of 7.42% during the forecast period of 2026-2035, likely to reach a market value of USD 72.52 Billion by 2035.
The rising burden of chronic diseases and the growing population size are fuelling the demand for the market.
One of the significant trends in the market is the increasing merger and acquisition activities among key market players. To gain entry into the South African market and strengthen its OTC drug offerings, Cipla Limited signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African OTC and generic medicines pharmaceutical company in September 2023.
Based on the therapy area, the market is segmented into cardiovascular, dermatology, respiratory, oncology, and rheumatology, among others.
By route of administration, the market is divided into oral, injectables, dermal/topical, and inhalers, among others.
The distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The market segmentation by countries includes UAE, Saudi Arabia, and Egypt, among others.
The key players in the market are Teva Pharmaceutical Industries Ltd., Viatris Inc., AstraZeneca, Baxter, GSK plc, Bausch + Lomb, Novartis AG, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA, and Hikma Pharmaceuticals PLC.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy Area |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share